Pre-treatment integrase inhibitor resistance is uncommon in ART-naïve individuals with HIV-1 subtype A1 and D infections in Uganda

OBJECTIVE: Dolutegravir (DTG) is now a preferred component of first-line antiretroviral therapy (ART). However, prevalence data on natural resistance to integrase inhibitors (INSTIs) in circulating non-subtype B HIV-1 in sub-Saharan Africa is scarce. Our objective is to report prevalence of pre-trea...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:AIDS
Main Authors: MCCLUSKEY, Suzanne M., KAMELIAN, Kimia, MUSINGUZI, Nicholas, KIGOZI, Simone, BOUM, Yap, BWANA, Mwebesa B., MUZOORA, Conrad, BRUMME, Zabrina L., CARRINGTON, Mary, CARLSON, Jonathan, FOLEY, Brian, HUNT, Peter W., MARTIN, Jeffrey N., BANGSBERG, David R., HARRIGAN, P. Richard, SIEDNER, Mark J., HABERER, Jessica E., LEE, Guinevere Q.
Formato: Artigo
Idioma:Inglês
Publicado: 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8102316/
https://ncbi.nlm.nih.gov/pubmed/33635845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAD.0000000000002854
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares